Small molecule profiling to define synergistic EGFR inhibitor combinations in head and neck squamous cell carcinoma

BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is a debilitating disease with poor survival. Although epidermal growth factor receptor (EGFR)‐targeting antibody cetuximab improves survival in some settings, responses are limited suggesting that alternative approaches are needed. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Michmerhuizen, Nicole L., Ludwig, Megan L., Birkeland, Andrew C., Nimmagadda, Sai, Zhai, Jingyi, Wang, Jiayu, Jewell, Brittany M., Genouw, Dylan, Remer, Lindsay, Kim, Daniel, Foltin, Susan K., Bhangale, Apurva, Kulkarni, Aditi, Bradford, Carol R., Swiecicki, Paul L., Carey, Thomas E., Jiang, Hui, Brenner, J. Chad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986607/
https://www.ncbi.nlm.nih.gov/pubmed/35224804
http://dx.doi.org/10.1002/hed.27018

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8986607/
https://www.ncbi.nlm.nih.gov/pubmed/35224804
http://dx.doi.org/10.1002/hed.27018

Ejemplares similares